Navigation Links
Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
Date:5/29/2008

Overall Market Growth Will be Driven by Launch of Nine Emerging Therapies,

Including Five Oral Agents, According to a New Report from Decision

Resources

WALTHAM, Mass., May 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highly anticipated launch of the first oral agents formally approved for multiple sclerosis will drive market growth as these therapies, combined, will garner 25 percent market share in 2017.

The new Pharmacor report entitled Multiple Sclerosis estimates that Novartis/Mitsubishi Tanabe's oral agent, FTY-720 (fingolimod) will capture nearly $900 million by 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, representing the greatest market share of any emerging multiple sclerosis therapy over the next decade. The report finds that, despite limited patient share, sales of FTY-720 will be driven by its improved efficacy, acceptable safety profile, and added convenience. The launch of nine emerging therapies-including five oral drugs-will drive moderate four percent annual growth through 2017 in the multiple sclerosis drug market. Rapid uptake of premium-priced oral drugs and the growing use of monoclonal antibodies, particularly in the United States, will spark this growth.

The report also finds that other strong contenders in the multiple sclerosis market over the next 10 years will include Merck Serono's oral cladribine (Mylinax), BioMS Medical/Eli Lilly's MBP-8298, and alemtuzumab, which is marketed in the U.S. as Campath for B-cell chronic lymphocytic leukemia by Bayer HealthCare and Genzyme Oncology. Oral cladribine's first-to- market status among emerging oral agents, MBP-8298's approval for secondary progressive multiple sclerosis and alemtuzumab's impressive efficacy will drive major-market peak-year sales for each drug to the range of $500 million to $1 billion.

"Oral cladribine, which will launch in 2010 and be the first emerging oral agent to market, will experience considerable initial uptake," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "In contrast, while alemtuzumab's efficacy and its convenient once-yearly dosing have impressed interviewed experts, possible safety risks could limit its uptake. Additionally, MBP-8298, which will be approved for secondary progressive multiple sclerosis, will provide a much-needed therapeutic option for this niche population."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biological electron transfer captured in real time
2. AbelsonTaylor Captures DTC Gold
3. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
4. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
5. Researchers outline structure of largest nonvirus particle ever crystallized
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
8. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
9. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
10. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
11. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on ... performed on a 55-year-old practicing female physician suffering from degenerative disc disease with ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... President and Chief Commercial Officer with GenePeeks. Matt is a veteran life ... is a computational genomics company focused on identifying inherited disease risk in future ...
Breaking Biology Technology:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
Breaking Biology News(10 mins):